tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inventiva (IVA) Gets a Buy from Canaccord Genuity

Inventiva (IVA) Gets a Buy from Canaccord Genuity

In a report released today, Edward Nash from Canaccord Genuity reiterated a Buy rating on Inventiva (IVAResearch Report), with a price target of $20.00. The company’s shares closed yesterday at $2.94.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Nash is a 5-star analyst with an average return of 15.8% and a 43.21% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Travere Therapeutics, and Verona Pharma.

Inventiva has an analyst consensus of Strong Buy, with a price target consensus of $14.80, representing a 403.40% upside. In a report released on March 28, H.C. Wainwright also maintained a Buy rating on the stock with a $13.00 price target.

Based on Inventiva’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.73 million and a GAAP net loss of $49.03 million. In comparison, last year the company earned a revenue of $6.62 million and had a GAAP net loss of $55.27 million

Disclaimer & DisclosureReport an Issue

1